Dupilumab in Japanese patients with chronic rhinosinusitis with nasal polyp (SINUS-M52)

Trial Identifier:	LPS16872
Sponsor:	Sanofi
Collaborator:	Regeneron Pharmaceuticals
Start Date:	October 2021
Primary Completion Date:	December 2022
Study Completion Date:	July 2023
Condition:	Nose and Sinus Disorder

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Japan	Japan, Japan

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.